After completing my basic medical education (MBBS), I did post graduate medical training (MD) from Delhi University in general internal medicine. Subsequently, I was awarded a prestigious World Bank Scholarship to do Master of Science (MSc) in epidemiology from London School of Hygiene and Tropical Medicine (University of London). I did my PhD in the field of cardiovascular and metabolic medicine, from Imperial College London.
I have extensive experience in general internal medicine, with particular interest (and expertise) in field of preventive cardiovascular and metabolic medicine (in particular sub-specialities of hypertension and diabetes). Over last several years, I have been working as a clinical researcher, and epidemiologist in ICCH, National Heart and Lung institute, where I have gained an excellent experience of population health research, and clinical trials design and management. I have several high impact publications (see publications), and have developed an expertise in various aspects of clinical trial design & methodology, biostatistics, and analyses of large popublation- or clinical trial - based data-bases. In addition, I have been a member of several end-point and safety adjudication committees of variaous trials and studies.
My research interests are mainly around epidemiology and therapeutics related to the field of cardiovascular and metabolic medicine; in particular my research focus is on the cardiovascular risk factors (including hypertension, obesity, diabetes, and hypercholesterolemia), their treatment and the interventions that can influence their relationship (in preventative aspect) with the cardiovascular outcomes or new-onset diabetes. Therefore, I have a great interest in developing risk scores and risk prediction models for these diseases. I am also interested on the therapeutics (and the management aspects) in this area, including evaluating the efficacy and utility of various cardiovascular medicines (such as antihypertensive agents, statins, oral hypoglycaemic agents, and anticoagulants treatment).
My other research focus is in the area related to the ethnic differences in the response and efficacy of these medications, and I am interested in exploring the relationship and influence of the ethnicity with the cardiovascular risk factors and outcomes, particularly among south Asian and Asian populations. In past, I have used the databases of large and small clinical trials, and have developed an interest (and understanding) in other aspects of clinical trials, including the safety and end-point adjudication and the database management.
As a natural extension of above two, I am interested in the pharmacovigilance and pharmacoepidemiology related to the cardiovascular and metabolic medicine. Previously, whilst doing several meta-analyses (to answer my research questions) I have used data from published work; I am now interested in trying to develop a research programme which (in addition to generating new data) proactively and more efficiently uses previously published data (in various trials, studies and surveys) to answer more some of the remaining research questions; thereby delivering tangible research outputs at significantly lower costs.
et al., 2018, Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial, The Lancet, Vol:392, ISSN:0140-6736, Pages:1127-1137